21 Gy single fraction prostate HDR brachytherapy: 5-year results of a single institution prospective pilot study.

Kamran SalariAllison J HazyHong YeEvelyn SebastianAmy LimbacherMatthew JohnsonBeth MitchellAndrew B ThompsonZachary A SeymourSirisha R NandalurDaniel J Krauss

Published in: Brachytherapy (2024)

21 Gy single fraction HDR brachytherapy was associated with modestly higher-than-anticipated chronic urinary toxicity, as well as high biochemical and local failure rates. The results from this prospective pilot study do not support the use of this regimen in standard clinical practice.

Keyphrases

high dose
clinical practice
radiation therapy
prostate cancer
locally advanced
oxidative stress
low dose
squamous cell carcinoma
benign prostatic hyperplasia
oxide nanoparticles